Akèy › Maladi fwa steatotik › Maryland
Etid klinik pou Maladi fwa steatotik nan Maryland
8 etid pou Maladi fwa steatotik ap chèche patisipan nan sit nan Maryland.
Vil nan Maryland
Tèks ofisyèl etid la (Anglè)
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Mercy Medical Center - Baltimore, Baltimore
- Capital Digestive Care - Chevy Chase, Chevy Chase
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Baltimore
- Akero Clinical Study Site, Bethesda
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Sep 21, 2026 · NCT06528314A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Mid-Atlantic GI Research, Greenbelt
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 9, 2026 · NCT07288138A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Baltimore
- 89bio Clinical Study Site, Glen Burnie
- 89bio Clinical Study Site, Greenbelt
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Sep 3, 2026 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Baltimore
- 89bio Clinical Study Site, Glen Burnie
- 89bio Clinical Study Site, Greenbelt
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 3, 2026 · NCT06419374Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 2Volontè an sante akeyi
Laj 18 a 100 · Tout sèks · Mizajou Aug 10, 2026 · NCT03884075Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 1Volontè an sante akeyi
Laj 21 a 65 · Tout sèks · Mizajou Jul 20, 2026 · NCT04781322A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, Baltimore
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Jul 8, 2026 · NCT06920043Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.